Idorsia Raises $630m For Daridorexant Launch And Pipeline Push
Insomnia Drug Submission Soon
With the US filing of its non-sedative sleeping pill now imminent, the Swiss biotech is also adding to its war chest to advance Phase III drugs aprocitentan, clazosentan and lucerastat.
You may also be interested in...
Idorsia, the Swiss company spun out of Actelion after the latter was bought by J&J, is to get another windfall from the US major which has triggered an option to co-develop the Phase III-ready drug aprocitentan.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.